Neo Borocillina Fluidificante Tosse (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Neo Borocillina Fluidificante Tosse, is a mucolytic presented as an oral formulation for oral use. It helps to loosen thick mucus in the airways, facilitating expectoration in patients with productive coughs and related respiratory conditions, and is indicated for use in adults and children.

GNH USA supplies Neo Borocillina Fluidificante Tosse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Ambroxol is a mucolytic that acts on respiratory secretions to improve clearance in several common airway conditions.

- Productive cough: reduces mucus viscosity, aiding expectoration. - Acute bronchitis: facilitates mucus clearance, helping relieve cough. - Upper respiratory tract infections: assists in thinning secretions, supporting symptom relief.

Ambroxol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Altered taste, often described as bitter or salty. - Nausea or mild gastrointestinal discomfort. - Diarrhea or loose stools.

Serious or Rare Side Effects: - Allergic reactions such as rash, urticaria or angioedema. - Severe skin reactions including Stevens‑Johnson syndrome. - Hepatic enzyme elevations or liver dysfunction.

When using Ambroxol, certain precautions should be observed to ensure safe and effective therapy.

- Pediatric use: dosage and duration should follow prescriber guidance, especially in children under two years. - Hepatic impairment: consider reduced dosing or monitoring in patients with liver disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Asthma: monitor for bronchospasm, although rare, in patients with reactive airway disease. - Concomitant mucolytics: avoid simultaneous use of multiple mucolytic agents without medical advice. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight in the original packaging.

Ambroxol can interact with other medicines, and the nature of the interaction determines the level of monitoring required.

Major Interactions (Avoid): - Combined use with other mucolytic agents (e.g., N‑acetylcysteine) may increase risk of bronchospasm. - Concomitant administration with known hypersensitivity‑inducing drugs in patients with a history of allergic reactions.

Moderate Interactions (Monitor Closely): - Antacids may reduce oral absorption of ambroxol, potentially lowering efficacy. - Drugs metabolized by CYP2D6 (e.g., certain antidepressants) could have altered plasma levels, requiring observation. - Bronchodilators (β2‑agonists) may have additive cough‑suppressing effects; monitor therapeutic response.